1961 was a momentous year that marked the development of medical and scientific research on cannabis. During that time, the United Nations (UN) determined the prohibition of cannabis use. Six decades later, this situation continues in the same way.
The Hemp.im mobile application was created to facilitate the search for information about cannabis from around the world. Our app is currently a global reference on the web for information about marijuana reports, medical uses, science, warnings, research and much more.
The Commission on Narcotic Drugs is part of the UN Economic and Social Council, the body responsible for amending, reviewing and periodically updating the list of prohibited substances, based on the recommendations of the World Health Organization, which in turn is advised by the Expert Committee on Drug Dependence.
The UN postponed the vote to remove cannabis from the list of prohibited substances
The historic vote was scheduled to take place this week and was aimed at reducing restrictions on scientific research and medical use in various regions of the world. According to the news agency EFE, the main reason for the postponement is to clarify the implications and consequences of such a decision, taking into account its complexity.
It should be noted that, since the 1960s, cannabis research faced many challenges and the prevailing limitations prevent the benefit for millions of patients. This situation resulted in a very significant scientific backlog, which from the legal field is difficult to overcome without the support of the agency.
Cannabis continues to be a banned substance
It is important to point out that this discussion arose as a result of the recommendation issued by the World Health Organization to eliminate cannabis from the list of prohibited substances, endorsed by the UN Commission on Narcotic Drugs. The recommendation was based on the argument that there is scientific evidence linking cannabis to healing processes, such as the virtues of cannabidiol oil (CBD).
With regard to CBD, the WHO is in favor of its legalization, as long as inputs containing it are shown to have less than 0.2% THC, the psychoactive element of cannabis. “Less control would allow for more scientific research into possible medical uses. At the same time, the new recommended level of control would ensure sufficient restrictions to protect against consumer damage,” a WHO spokesman said.
WHO and cannabis
The WHO also stated that cannabis should be subject to a control guarantee that prevents users from exceeding a consumption limit to avoid harm, and which guarantees access to inputs related to this plant for medical use and scientific research. This fact shatters the illusions of dozens of researchers from various regions around the world, who were looking forward to the meeting to be held this week in Vienna, in hopes of continuing their research work.
Another important issue to be addressed on cannabis is the dynamics with regard to its control at the international level, in particular, to facilitate the functioning of commercial use, which would benefit both employers and patients. It is worth noting that the conferences that postponed the discussion were grouped into five geographical blocks: Latin America and the Caribbean, Africa, Asia, Eastern, and Western Europe, which includes the United States, the United Kingdom, Canada, and Australia.
UN is left without an agreement
Despite this, it should be noted that the public meeting of the representatives lasted only 45 minutes. That was in order to avoid further tensions around cannabis and its possible consequences.
The position of nations such as China and Russia, of the African and Asian blocks, as well as of Latin America, are fundamental in future negotiations.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in NACION CANNABIS, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Sono Motors introduces community advisory board
Sono Motors unveiled the latest prototype of its electric minivan with solar cells in the body. In parallel with the...
Ysios Capital invests 30 million in 2020 and plans to enter four companies in 2021
In a year marked by the COVID-19 pandemic, the venture capital manager Ysios Capital carried out six follow-on operations and...
Oxxo enters the fintech ecosystem with its digital wallet Spin
On March 2nd, Oxxo presented Spin, a digital wallet through which it will be possible to manage, send and receive...
AEDESEO asks for €57,000 in crowdfunding to research a new treatment
AEDESO wants to start a clinical study and launched a crowdfunding campaign to raise the necessary money for it. Patients...
Mainz-based biotech company ActiTrexx receives €3.5 million in financing
The biotech company ActiTrexx has recently closed a Series A financing round, during which it raised $4.2 million (€3.5 million)....
Biotech6 days ago
VB Devices closes a €1.1 million round to consolidate its market entry
Business7 days ago
The multifaceted benefits of Augmented and Virtual Reality in education
Featured7 days ago
ARisk, the startup of predictive risk algorithms, closes €350,000 round
Cannabis6 days ago
Legalization trend drives cannabis ETFs to significantly grow